Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.68 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491896 | 1.00 | PTGS2 (0.68) | PTGS2AKR1C3CNR2KDM4EMEN1 | |
| SCHEMBL8702796 | 0.85 | PTGS2 (0.69) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL14761129 | 0.84 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL12336880 | 0.84 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL9235971 | 0.84 | PTGS2 (0.74) | PTGS2AKR1C3CNR2KDM4EMEN1 | |
| SCHEMBL10592773 | 0.83 | PTGS2 (0.78) | PTGS2AKR1C3CNR2KDM4EMEN1 | |
| SCHEMBL7618146 | 0.82 | PTGS2 (0.79) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL7618152 | 0.82 | PTGS2 (0.79) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL2739299 | 0.82 | PTGS2 (1.00) | PTGS2AKR1C3CNR2KDM4EMEN1 | |
| SCHEMBL2493085 | 0.81 | PTGS2 (0.72) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065934-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | claimed |
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-9216224-B2 | Fatty acid COX inhibitor derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2949344-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | Catabasis Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2685969-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | Catabasis Pharmaceuticals, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20130065934-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2012129112-A2 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2011109681-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | PTGES, PTGES2, ALOX5 | PTGS2 7/4885AKR1C3 626/4885CNR2 267/4885 |
| US-20140315786-A1 | USE OF INTRACELLULAR ENZYMES FOR THE RELEASE OF COVALENTLY LINKED BIOACTIVES | GAA, GUSB, ACER2 | PTGS2 1008/4885AKR1C3 1084/4885CNR2 3425/4885 |
| US-20130065934-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | PTGES, ALOX5, PTGES2 | PTGS2 7/4885AKR1C3 603/4885CNR2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.